# Endocrine Response in Women With Invasive Lobular Breast Cancer

> **NCT02206984** · PHASE2 · COMPLETED · sponsor: **Priscilla McAuliffe** · enrollment: 201 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Tamoxifen
- **DRUG:** Anastrozole
- **DRUG:** Fulvestrant

## Key facts

- **NCT ID:** NCT02206984
- **Lead sponsor:** Priscilla McAuliffe
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09-30
- **Primary completion:** 2024-07-19
- **Final completion:** 2024-07-19
- **Target enrollment:** 201 (ACTUAL)
- **Last updated:** 2025-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02206984

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02206984, "Endocrine Response in Women With Invasive Lobular Breast Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02206984. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*